On a mission to make organ transplants safer and more durable, Blackstone gifts Talaris a new CEO, leads $100M round
As a transplant surgeon by training, Suzanne Ildstad understood the plight of her patients all too well: The risk of organ rejection forces them to adopt immunosuppression regimens, which in turn expose them to infections and cardiovascular problems they have to contend with. She knew that if the bone marrow from a donor takes, any subsequent organ transplant would, too.
“We discovered a cell in the bone marrow called the facilitating cells that is CD8 positive and T cell receptor negative, and it helps the stem cell to take,” Ildstad, director of the University of Louisville’s Institute of Cell Therapy, said. “From that we developed a method to process the bone marrows from humans to essentially take out the bad cells and leave in the good cells.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
